Recruiting

New liver cancer treatment combining two immunotherapy drugs with a targeted perfusion procedure

Plain-English translation of NCT06519266 on ClinicalTrials.gov ↗ · Source last updated November 2024 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether a combination of two immunotherapy drugs — ipilimumab and nivolumab — works better when paired with a procedure called percutaneous hepatic perfusion (PHP), which delivers chemotherapy directly to tumors in the liver. The study compares this combination approach to immunotherapy drugs alone in people whose melanoma (a type of eye cancer) has spread to the liver.

When melanoma from the eye spreads to the liver, it is very hard to treat and survival is usually quite short—about 6 months on average. Researchers want to see if delivering medication directly to the liver tumors through this specialized procedure, combined with immunotherapy, can help patients live longer and keep their cancer from growing.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with uveal melanoma (eye cancer) that has spread to your liver and can be seen on a CT scan
you have not received previous treatment for your melanoma metastases (unless you had surgery, ablation, or prior immunotherapy that didn't work)
you are physically able to undergo general anesthesia and are deemed suitable for the liver perfusion procedure
you have adequate kidney, liver, and blood cell function based on blood tests
if you are a woman who can become pregnant, you are willing to use birth control during and for 5 months after treatment

You likely don't qualify if…

you have severe heart disease, lung disease, or other serious conditions that would prevent you from having general anesthesia
you have significant liver damage or cirrhosis, or if more than half of your liver is replaced by tumor
you have cancer that has spread outside the liver
you have a history of severe allergic reactions to antibody drugs, chemotherapy, or contrast dye
you have HIV, AIDS, hepatitis B or C, or an active autoimmune disease

What participation looks like

Participants will be randomly assigned to one of two groups. One group will receive four doses of the two immunotherapy drugs given through an IV over 12 weeks, followed by continued treatment for up to a year. The other group will first receive two rounds of the specialized liver perfusion procedure (6 weeks apart), then receive four doses of immunotherapy drugs given at different doses, followed by continued treatment for up to a year. Throughout the trial, you'll have regular CT scans, blood tests, and clinic visits to monitor how well the treatment is working and check for side effects.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

New liver cancer treatment combining two immunotherapy drugs with a targeted perfusion procedure

What is this trial?

Do you qualify?

What participation looks like

Trial locations